Oral abrocitinib in the treatment of granuloma annulare: a case report.
J Dermatolog Treat
; 35(1): 2313090, 2024 Dec.
Article
em En
| MEDLINE
| ID: mdl-38317538
ABSTRACT
Aim:
To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English.Methods:
We presented a patient who had a persistent, localized granuloma anulare (GA) for one year and did not respond to traditional therapies. This patient was treated with oral abrocitinib at a dosage of 150 mg daily.Results:
After 6 weeks of treatment with abrocitinib, the patient exhibited notable symptom improvement with no new lesions. No adverse events or recurrences were reported during the 5-month follow-up period.Conclusions:
Abrocitinib may be a promising and safe treatment option for patients with localized GA who do not respond to traditional therapies.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Granuloma Anular
/
Inibidores de Janus Quinases
Limite:
Humans
Idioma:
En
Revista:
J Dermatolog Treat
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article